The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 337:956-962 October 2, 1997 Number 14
NextNext

Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Joseph Ragaz, Stewart M. Jackson, Nhu Le, Ian H. Plenderleith, John J. Spinelli, Vivian E. Basco, Kenneth S. Wilson, Margaret A. Knowling, Christopher M.L. Coppin, Marilyn Paradis, Andrew J. Coldman, and Ivo A. Olivotto

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Radiotherapy after mastectomy to treat early breast cancer has been known since the 1940s to reduce rates of local relapse. However, the routine use of postoperative radiotherapy began to decline in the 1980s because it failed to improve overall survival. We prospectively tested the efficacy of combining radiotherapy with chemotherapy.

Methods From 1978 through 1986, 318 premenopausal women with node-positive breast cancer were randomly assigned, after modified radical mastectomy, to receive chemotherapy plus radiotherapy or chemotherapy alone. Radiotherapy was given to the chest wall and locoregional lymph nodes between the fourth and fifth cycles of cyclophosphamide, methotrexate, and fluorouracil.

Results After 15 years of follow-up, the women assigned to chemotherapy plus radiotherapy had a 33 percent reduction in the rate of recurrence (relative risk, 0.67; 95 percent confidence interval, 0.50 to 0.90) and a 29 percent reduction in mortality from breast cancer (relative risk, 0.71; 95 percent confidence interval, 0.51 to 0.99), as compared with the women treated with chemotherapy alone.

Conclusions Radiotherapy combined with chemotherapy after modified radical mastectomy decreases rates of locoregional and systemic relapse and reduces mortality from breast cancer.


Source Information

From the Departments of Medical Oncology (J.R., I.H.P., M.A.K., C.M.L.C.) and Radiation Oncology (S.M.J., V.E.B., M.P., I.A.O.), the Cancer Control Research Unit (N.L.), and the Cancer Control Strategy Process (A.J.C.), British Columbia Cancer Agency, Vancouver; the Department of Health Care and Epidemiology, University of British Columbia, Vancouver (J.J.S.); the Health Research Centre, St. Paul's Hospital, Vancouver (J.J.S.); and the Department of Medical Oncology, British Columbia Cancer Agency, Victoria (K.S.W.) — all in British Columbia, Canada.

Address reprint requests to Dr. Ragaz at Medical Oncology, British Columbia Cancer Agency, 600 W. 10th Ave., Vancouver, BC V5Z 4E6, Canada.

Full Text of this Article


Related Letters:

Radiotherapy and Chemotherapy in High-Risk Breast Cancer
El-Tamer M., Homel P., Braverman A. S., Wolberg W. H., Robins H. I., Goldhirsch A., Coates A. S., Colleoni M., Gelber R. D., Raffle A.E., Evans R. A., Overgaard M., Rose C., Mouridsen H., Ragaz J., Jackson S. M., Spinelli J. J., Hellman S.
Extract | Full Text  
N Engl J Med 1998; 338:329-333, Jan 29, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.